JOHNSON & JOHNSON shareholders Q2 2018

JOHNSON & JOHNSON's ticker is JNJ and the CUSIP is 478160104. A total of 2,582 filers reported holding JOHNSON & JOHNSON in Q2 2018. The put-call ratio across all filers is 1.27 and the average weighting 1.2%.

JOHNSON & JOHNSON shareholders Q2 2018
NameSharesValueWeighting ↓
EARNEST PARTNERS LLC 1,272$154,0000.00%
CLEARBRIDGE, LLC 712$86,0000.00%
HighTower Advisors, LLC 53,800$164,0000.00%
Mondrian Investment Partners LTD 251$30,0000.00%
Balentine LLC 70$8,0000.00%
TD AMERITRADE INVESTMENT MANAGEMENT, LLC 400$49,0000.00%
SMITH ASSET MANAGEMENT GROUP LP 27$3,0000.00%
Magellan Asset Management Ltd 84$10,0000.00%
Bluefin Trading, LLC 16,000$1,0000.00%
Creative Planning 100$3,0000.00%
Invesco Ltd. 2,800$340,0000.00%
Kovack Advisors, Inc. 2$1,0000.00%
DEUTSCHE BANK AG\ 2,434$295,0000.00%
Kingsview Wealth Management, LLC 1,000$1,0000.00%
WELLS FARGO & COMPANY/MN 66,500$80,0000.00%
Kingsview Wealth Management, LLC 300$1,0000.00%
WELLS FARGO & COMPANY/MN 144,127$1,158,0000.00%
Financial Engines Advisors L.L.C. 135$16,0000.00%
About JOHNSON & JOHNSON

Johnson & Johnson is a multinational corporation that specializes in the production of medical devices, pharmaceuticals, and consumer goods. The company was founded in 1886 and has since become a household name in the healthcare industry. With a market capitalization of over $400 billion, Johnson & Johnson is one of the largest healthcare companies in the world.

The company's success can be attributed to its commitment to innovation and quality. Johnson & Johnson invests heavily in research and development, with a focus on developing new treatments for a variety of medical conditions. The company's pharmaceutical division is responsible for the development of many life-saving drugs, including treatments for cancer, HIV, and diabetes.

In addition to its pharmaceuticals, Johnson & Johnson is also known for its consumer goods. The company produces a wide range of products, including baby care items, skincare products, and over-the-counter medications. Many of these products are household names, such as Band-Aid, Tylenol, and Neutrogena.

Despite its success, Johnson & Johnson has faced its fair share of challenges. In recent years, the company has been involved in several high-profile lawsuits related to the safety of its products. However, the company has taken steps to address these issues and remains committed to providing safe and effective products to its customers.

Overall, Johnson & Johnson is a company that has made significant contributions to the healthcare industry. With its focus on innovation and quality, the company is well-positioned to continue its success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists JOHNSON & JOHNSON's shareholders in Q2 2018. To view JOHNSON & JOHNSON's shareholder history, click here.